French laboratories form cancer diagnostics alliance
This article was originally published in Clinica
French drug discovery company ExonHit Therapeutics and diagnostics company bioMerieux-Pierre Fabre have entered a five-year deal to develop ExonHit's Proof-Hit breast and colon cancer diagnostic tool. The companies, both Paris-based, say that combining their respective expertise will provide new cancer therapeutics and develop the required diagnostics to devise and apply personalised medicines.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.